Seminars in Nephrology
Volume 29, Issue 1 , Pages 3-14 , January 2009

Why Is Protein–Energy Wasting Associated With Mortality in Chronic Kidney Disease?

  • Csaba P. Kovesdy, MD

      Affiliations

    • Division of Nephrology, Salem Veterans Affairs Medical Center, Salem, VA
    • Department of Medicine, University of Virginia, Charlottesville, VA
    • Corresponding Author InformationAddress reprint requests to Csaba P. Kovesdy, MD, Division of Nephrology Salem Veterans Affairs Medical Center (111D), 1970 Roanoke Blvd, Salem, VA 24153
    • ,
  • Kamyar Kalantar-Zadeh, MD, MPH, PhD

      Affiliations

    • Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA
    • David Geffen School of Medicine at UCLA, Los Angeles, CA

References 

  1. U.S. Renal Data System. USRDS 2007 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007;
  2. Kovesdy CP, Trivedi BK, Anderson JE. Association of kidney function with mortality in patients with chronic kidney disease not yet on dialysis: a historical prospective cohort study. Adv Chronic Kidney Dis. 2006;13:183–188
  3. Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659–663
  4. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248
  5. Kalantar-Zadeh K, Block G, Humphreys MH, et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63:793–808
  6. Fleischmann EH, Bower JD, Salahudeen AK. Risk factor paradox in hemodialysis: better nutrition as a partial explanation. ASAIO J. 2001;47:74–81
  7. Kopple JD. How to reconcile conventional and altered risk factor patterns in dialysis patients. Semin Dial. 2007;20:602–605
  8. Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73:391–398
  9. Kovesdy CP, Kalantar-Zadeh K. Introduction: the reverse epidemiology controversy. Semin Dial. 2007;20:485
  10. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, et al. Survival advantages of obesity in dialysis patients. Am J Clin Nutr. 2005;81:543–554
  11. Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, et al. Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis. 2005;46:489–500
  12. Schmidt DS, Salahudeen AK. Obesity-survival paradox-still a controversy?. Semin Dial. 2007;20:486–492
  13. Kalantar-Zadeh K, Kopple JD. Obesity paradox in patients on maintenance dialysis. Contrib Nephrol. 2006;151:57–69
  14. Kilpatrick RD, McAllister CJ, Kovesdy CP, et al. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol. 2007;18:293–303
  15. Baigent C, Landray MJ, Wheeler DC. Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trials. Semin Dial. 2007;20:498–503
  16. Shinaberger CS, Kilpatrick RD, Regidor DL, et al. Longitudinal associations between dietary protein intake and survival in hemodialysis patients. Am J Kidney Dis. 2006;48:37–49
  17. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, et al. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant. 2005;20:1880–1888
  18. Menon V, Greene T, Wang X, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int. 2005;68:766–772
  19. Muntner P, He J, Astor BC, et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol. 2005;16:529–538
  20. Weiner DE, Tighiouart H, Elsayed EF, et al. The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD. Am J Kidney Dis. 2008;51:212–223
  21. Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005;293:1737–1745
  22. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol. 2007;18:304–311
  23. Evans M, Fryzek JP, Elinder CG, et al. The natural history of chronic renal failure: results from an unselected, population-based, inception cohort in Sweden. Am J Kidney Dis. 2005;46:863–870
  24. Jurkovitz C, Li S, Bakris G, Brown W, McCullough P, Vassalotti J, et al. Effect of obesity on mortality in patients at high risk for kidney disease: results from KEEP. [abstract] J Am Soc Nephrol. 2006;17:11A
  25. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Paradoxical association between body mass index and mortality in men with CKD not yet on dialysis. Am J Kidney Dis. 2007;49:581–591
  26. Kwan BC, Murtaugh MA, Beddhu S. Associations of body size with metabolic syndrome and mortality in moderate chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:992–998
  27. Madero M, Sarnak MJ, Wang X, et al. Body mass index and mortality in CKD. Am J Kidney Dis. 2007;50:404–411
  28. Curtis JP, Selter JG, Wang Y, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med. 2005;165:55–61
  29. Escalante A, Haas RW, del RI. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med. 2005;165:1624–1629
  30. Wilson DO, Rogers RM, Wright EC, et al. Body weight in chronic obstructive pulmonary disease (The National Institutes of Health Intermittent Positive-Pressure Breathing Trial). Am Rev Respir Dis. 1989;139:1435–1438
  31. Hill AB. The environment and disease: association or causation?. Proc R Soc Med. 1965;58:295–300
  32. Kopple JD, Zhu X, Lew NL, et al. Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int. 1999;56:1136–1148
  33. Kopple JD. McCollum Award Lecture, 1996: protein-energy malnutrition in maintenance dialysis patients. Am J Clin Nutr. 1997;65:1544–1557
  34. Kalantar-Zadeh K, Kopple JD. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am J Kidney Dis. 2001;38:1343–1350
  35. Argiles JM. Cancer-associated malnutrition. Eur J Oncol Nurs. 2005;9(Suppl 2):S39–S50
  36. Lee PS, Waxman AB, Cotich KL, et al. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med. 2007;35:849–855
  37. Rothenbach PA, Dahl B, Schwartz JJ, et al. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J Appl Physiol. 2004;96:25–31
  38. Christofidou-Solomidou M, Scherpereel A, Solomides CC, et al. Recombinant plasma gelsolin diminishes the acute inflammatory response to hyperoxia in mice. J Investig Med. 2002;50:54–60
  39. Chinen J, Shearer WT. Secondary immunodeficiencies, including HIV infection. J Allergy Clin Immunol. 2008;121:S388–S392
  40. Kalantar-Zadeh K, Kopple J. Malnutrition as a cause of morbidity and mortality in dialysis patients. In:  Kopple J,  Massry S editor. Nutritional management of renal disease. Philadelphia: Lippincott, Williams & Wilkins; 2004;
  41. Hulsewe KW, van Acker BA, von Meyenfeldt MF, et al. Nutritional depletion and dietary manipulation: effects on the immune response. World J Surg. 1999;23:536–544
  42. Souba WW. Nutritional support. N Engl J Med. 1997;336:41–48
  43. Alexander JW. Immunoenhancement via enteral nutrition. Arch Surg. 1993;128:1242–1245
  44. Kimmel PL, Phillips TM, Lew SQ, et al. Zinc modulates mononuclear cellular calcitriol metabolism in peritoneal dialysis patients. Kidney Int. 1996;49:1407–1412
  45. Erten Y, Kayatas M, Sezer S, et al. Zinc deficiency: prevalence and causes in hemodialysis patients and effect on cellular immune response. Transplant Proc. 1998;30:850–851
  46. Casciato DA, McAdam LP, Kopple JD, et al. Immunologic abnormalities in hemodialysis patients: improvement after pyridoxine therapy. Nephron. 1984;38:9–16
  47. Dobbelstein H, Korner WF, Mempel W, et al. Vitamin B6 deficiency in uremia and its implications for the depression of immune responses. Kidney Int. 1974;5:233–239
  48. DeSimone C, Famularo G, Tzantzoglou S, et al. Carnitine depletion in peripheral blood mononuclear cells from patients with AIDS: effect of oral L-carnitine. AIDS. 1994;8:655–660
  49. Vanholder R, Dell'Aquila R, Jacobs V, et al. Depressed phagocytosis in hemodialyzed patients: in vivo and in vitro mechanisms. Nephron. 1993;63:409–415
  50. Vanholder R, Van LA, Dhondt AM, et al. Influence of uraemia and haemodialysis on host defence and infection. Nephrol Dial Transplant. 1996;11:593–598
  51. Kalantar-Zadeh K, Daar ES, Eysselein VE, et al. Hepatitis C infection in dialysis patients: a link to poor clinical outcome?. Int Urol Nephrol. 2007;39:247–259
  52. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol. 2007;18:1584–1593
  53. Ritz E. Why are lipids not predictive of cardiovascular death in the dialysis patient?. Miner Electrolyte Metab. 1996;22:9–12
  54. Kaysen GA. Inflammation nutritional state and outcome in end stage renal disease. Miner Electrolyte Metab. 1999;25:242–250
  55. Bergstrom J, Lindholm B, Lacson E, et al. What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients?. Semin Dial. 2000;13:163–175
  56. Menon V, Wang X, Greene T, et al. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis. 2003;42:44–52
  57. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  58. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843
  59. Kalantar-Zadeh K, Block G, McAllister CJ, et al. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr. 2004;80:299–307
  60. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126
  61. Ling PR, Smith RJ, Kie S, et al. Effects of protein malnutrition on IL-6-mediated signaling in the liver and the systemic acute-phase response in rats. Am J Physiol Regul Integr Comp Physiol. 2004;287:R801–R808
  62. Kalantar-Zadeh K, Ikizler TA, Block G, et al. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003;42:864–881
  63. Dolson GM. Do potassium deficient diets and K+ removal by dialysis contribute to the cardiovascular morbidity and mortality of patients with end stage renal disease?. Int J Artif Organs. 1997;20:134–135
  64. Kalantar-Zadeh K, Kopple JD, Deepak S, et al. Food intake characteristics of hemodialysis patients as obtained by food frequency questionnaire. J Ren Nutr. 2002;12:17–31
  65. Ziegler TR, Evans ME, Fernandez-Estivariz C, et al. Trophic and cytoprotective nutrition for intestinal adaptation, mucosal repair, and barrier function. Annu Rev Nutr. 2003;23:229–261
  66. Jandacek RJ, Anderson N, Liu M, et al. Effects of yo-yo diet, caloric restriction, and olestra on tissue distribution of hexachlorobenzene. Am J Physiol Gastrointest Liver Physiol. 2005;288:G292–G299
  67. Mohamed-Ali V, Goodrick S, Bulmer K, et al. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol. 1999;277:E971–E975
  68. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet. 2000;356:930–933
  69. Kalantar-Zadeh K, Kopple JD, Kamranpour N, et al. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int. 2007;72:1149–1156
  70. Kovesdy CP, Kalantar-Zadeh K. Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int. 2008;73:1355–1363
  71. Kalantar-Zadeh K, Streja E, Kopple JD, McAllister CJ, Kovesdy CP. High platelet count is associated with lower iron stores and higher ESA dose in hemodialysis patients: a possible explanation for hemoglobin-survival paradox?. J Am Soc Nephrol. 2007;18:81A
  72. Kalantar-Zadeh K, Brennan ML, Hazen SL. Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2006;48:59–68
  73. Pupim LB, Flakoll PJ, Ikizler TA. Nutritional supplementation acutely increases albumin fractional synthetic rate in chronic hemodialysis patients. J Am Soc Nephrol. 2004;15:1920–1926
  74. Pupim LB, Majchrzak KM, Flakoll PJ, et al. Intradialytic oral nutrition improves protein homeostasis in chronic hemodialysis patients with deranged nutritional status. J Am Soc Nephrol. 2006;17:3149–3157
  75. Stratton RJ, Bircher G, Fouque D, et al. Multinutrient oral supplements and tube feeding in maintenance dialysis: a systematic review and meta-analysis. Am J Kidney Dis. 2005;46:387–405
  76. Czekalski S, Hozejowski R. Intradialytic amino acids supplementation in hemodialysis patients with malnutrition: results of a multicenter cohort study. J Ren Nutr. 2004;14:82–88
  77. Feldt-Rasmussen B, Lange M, Sulowicz W, et al. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol. 2007;18:2161–2171
  78. Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA. 1999;281:1275–1281
  79. Barton PA, Chretien C, Lau AH. The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients. Clin Nephrol. 2002;58:38–46
  80. Navarro JF, Mora C, Macia M, et al. Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney Int. 2002;61:1537–1544
  81. Galland R, Traeger J, Arkouche W, et al. Short daily hemodialysis rapidly improves nutritional status in hemodialysis patients. Kidney Int. 2001;60:1555–1560
  82. Galland R, Traeger J, Arkouche W, et al. Short daily hemodialysis and nutritional status. Am J Kidney Dis. 2001;37:S95–S98
  83. Cano NJ, Fouque D, Roth H, et al. Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study. J Am Soc Nephrol. 2007;18:2583–2591
  84. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  85. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  86. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010–2019

 The authors were supported by a research grant (R01 DK078106) from the National Institutes of Diabetes, Digestive and Kidney Disease of the National Institutes of Health. Dr. Kalantar-Zadeh has received grants or honoraria from NovoNordisk, the manufacturer of growth hormone; Abbott, the manufacturer of Nepro and Oxepa; and Nutripletion, the manufacturer of intradialytic parenteral nutrition. Dr. Kovesdy has no conflicts of interest to declare.

PII: S0270-9295(08)00165-4

doi: 10.1016/j.semnephrol.2008.10.002

Seminars in Nephrology
Volume 29, Issue 1 , Pages 3-14 , January 2009

Article Tools

* Image Usage & Resolution